ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.4332G>A (p.Lys1444=)

dbSNP: rs199474750
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000485227 SCV000573246 likely pathogenic not provided 2021-08-17 criteria provided, single submitter clinical testing Located at the last nucleotide of the exon and predicted to result in abnormal splicing leading to an in-frame deletion of the adjacent exon; Published functional studies demonstrate a damaging effect: cell lines containing this variant were able to form colonies and lost contact inhibition; they also showed the ability to form tumors when introduced to mice (Li 2016); Not observed at significant frequency in large population cohorts (Lek 2016); This variant is associated with the following publications: (PMID: 32978145, 28068329, 27617404, 27862945)
Medical Genetics, University of Parma RCV000497159 SCV000588779 likely pathogenic Neurofibromatosis, type 1 2022-08-17 criteria provided, single submitter clinical testing
Invitae RCV000497159 SCV000628581 pathogenic Neurofibromatosis, type 1 2023-10-04 criteria provided, single submitter clinical testing This sequence change affects codon 1423 of the NF1 mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the NF1 protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with neurofibromatosis type 1 (PMID: 21520333, 27862945, 28068329). ClinVar contains an entry for this variant (Variation ID: 423536). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of 27 bp, but is expected to preserve the integrity of the reading-frame (PMID: 28068329). This variant disrupts the c.4269G nucleotide in the NF1 gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 18546366). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Center for Human Genetics, Inc, Center for Human Genetics, Inc RCV000497159 SCV000782016 likely pathogenic Neurofibromatosis, type 1 2016-11-01 criteria provided, single submitter clinical testing
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein RCV000497159 SCV003806758 likely pathogenic Neurofibromatosis, type 1 2023-01-13 criteria provided, single submitter clinical testing ACMG classification criteria: PS3 supporting, PS4 supporting, PM2 moderated, PP1 supporting, PP3 supporting
Ambry Genetics RCV003168975 SCV003861744 likely pathogenic Hereditary cancer-predisposing syndrome; Cardiovascular phenotype 2023-03-01 criteria provided, single submitter clinical testing The c.4269G>A variant (also known as p.K1423K), located in coding exon 31 of the NF1 gene, results from a G to A substitution at nucleotide position 4269. This nucleotide substitution does not change the at codon 1423. However, this change occurs in the last base pair of coding exon 31, which makes it likely to have some effect on normal mRNA splicing. This alteration was reported in individuals who either had a clinical diagnosis of neurofibromatosis type 1(NF1) or had some clinical features of NF1 (Sites ER et al. Am J Med Genet A, 2017 Mar;173:647-653; Pemov A et al. Oncogene, 2017 Jun;36:3168-3177). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site; however, direct evidence is insufficient at this time (Ambry internal data). Based on the majority of available evidence to date, this variant is likely to be pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.